A phase three global clinical trial has shown that the drug vosoritide restores close-to-average bone growth rates of children with achondroplasia, the most common form of dwarfism. The study enrolled 121 children aged five to 18. The 60 children who received vosoritide grew an average 1.57 cm more per year. Regulatory authorities are reviewing applications to license treatment.
Related Posts
Order Antibiotics online
June 8, 2024Buying antibiotics online
June 8, 2024How do antibiotics work?
June 8, 2024Flagyl: a beacon of hope in the fight against trichomoniasis
February 17, 2024Metronidazole for bacterial infection
February 1, 2023